Pr Serge Lepage, M.D.Professeur titulaireMembre de l'axe de recherche "Diabète, obésité, et complications cardiovasculaires" du CRC-Étienne LeBel du CHUS. |
Service de cardiologie Département de médecine Faculté de médecine et des sciences de la santé Université de Sherbrooke 3001, 12e Avenue Nord Sherbrooke (Québec) J1H 5N4 Téléphone : 819 821-8000, poste 74947 Télécopieur : 819 820-6897 Courriel : Serge.Lepage@USherbrooke.ca |
Insuffisance cardiaque - Angine - Hypertension artérielle.
Diabète, obésité et complications cardiovasculaires.
Chercheur principal : Lepage S
Organisme commanditaire : Servier Canada inc.
The 2014 canadian cardiovascular society heart failure management guidelines focus update: anemia, biomarkers, and recent therapeutic trial implications.
Moe GW, Ezekowitz JA, O'Meara E, Lepage S, Howlett JG, Fremes S, Al-Hesayen A, Heckman GA, Abrams H, Ducharme A, Estrella-Holder E, Grzeslo A, Harkness K, Koshman SL, McDonald M, McKelvie R, Rajda M, Rao V, Swiggum E, Virani S, Zieroth S, Arnold JM, Ashton T, D'Astous M, Chan M, De S, Dorian P, Giannetti N, Haddad H, Isaac DL, Kouz S, Leblanc MH, Liu P, Ross HJ, Sussex B, White M.
Can J Cardiol. 2015 Jan;31(1):3-16. doi: 10.1016/j.cjca.2014.10.022. Epub 2014 Dec 19. PMID: 25532421
Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES).
Pieske B, Butler J, Filippatos G, Lam C, Maggioni AP, Ponikowski P, Shah S, Solomon S, Kraigher-Krainer E, Samano ET, Scalise AV, Müller K, Roessig L, Gheorghiade M; SOCRATES Investigators (Lepage S) and Coordinators.
Eur J Heart Fail. 2014 Sep;16(9):1026-38. doi: 10.1002/ejhf.135. Epub 2014 Jul 24. PMID: 25056511
Ivabradine in stable coronary artery disease without clinical heart failure.
Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R; SIGNIFY Investigators (Lepage S).
N Engl J Med. 2014 Sep 18;371(12):1091-9. doi: 10.1056/NEJMoa1406430. Epub 2014 Aug 31. PMID: 25176136
Angiotensin-neprilysin inhibition versus enalapril in heart failure.
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees (Lepage S).
N Engl J Med. 2014 Sep 11;371(11):993-1004. doi: 10.1056/NEJMoa1409077. Epub 2014 Aug 30. PMID: 25176015
Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study.
Montalescot G, Pitt B, Lopez de Sa E, Hamm CW, Flather M, Verheugt F, Shi H, Turgonyi E, Orri M, Vincent J, Zannad F; REMINDER Investigators (Lepage S).
Eur Heart J. 2014 Sep 7;35(34):2295-302. doi: 10.1093/eurheartj/ehu164. Epub 2014 Apr 29. PMID: 24780614
Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2).
Packer M, Carson P, Elkayam U, Konstam MA, Moe G, O'Connor C, Rouleau JL, Schocken D, Anderson SA, DeMets DL; PRAISE-2 Study Group (Lepage S).
JACC Heart Fail. 2013 Aug;1(4):308-14. doi: 10.1016/j.jchf.2013.04.004. Epub 2013 Aug 5. PMID: 24621933
Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.
Lincoff AM, Tardif JC, Schwartz GG, Nicholls SJ, Rydén L, Neal B, Malmberg K, Wedel H, Buse JB, Henry RR, Weichert A, Cannata R, Svensson A, Volz D, Grobbee DE; AleCardio Investigators (Lepage S).
JAMA. 2014 Apr 16;311(15):1515-25. doi: 10.1001/jama.2014.3321. PMID: 24682069
The 2013 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: focus on rehabilitation and exercise and surgical coronary revascularization.
Canadian Cardiovascular Society Heart Failure Management Primary Panel, Moe GW, Ezekowitz JA, O'Meara E, Howlett JG, Fremes SE, Al-Hesayen A, Heckman GA, Ducharme A, Estrella-Holder E, Grzeslo A, Harkness K, Lepage S, McDonald M, McKelvie RS, Nigam A, Rajda M, Rao V, Swiggum E, Virani S, Van Le V, Zieroth S; Canadian Cardiovascular Society Heart Failure Management Secondary Panel, Arnold JM, Ashton T, D'Astous M, Dorian P, Giannetti N, Haddad H, Isaac DL, Kouz S, Leblanc MH, Liu P, Ross HJ, Sussex B, White M.
Can J Cardiol. 2014 Mar;30(3):249-63. doi: 10.1016/j.cjca.2013.10.010. Epub 2013 Oct 19. Review. PMID: 24480445
Effect of age and sex on echocardiographic left ventricular diastolic function parameters in patients with preserved ejection fraction and normal valvular function.
Carvalho JC, Farand P, Do HD, Brochu MC, Bonenfant F, Lepage S.
Cardiol J. 2013;20(5):513-8. doi: 10.5603/CJ.2013.0137. PMID: 24469875
Gender and other disparities in referral to specialized heart failure clinics following emergency department visits.
Feldman DE, Huynh T, Des Lauriers J, Giannetti N, Frenette M, Grondin F, Michel C, Sheppard R, Montigny M, Lepage S, Nguyen V, Behlouli H, Pilote L.
J Womens Health (Larchmt). 2013 Jun;22(6):526-31. doi: 10.1089/jwh.2012.4107. PMID: 23751166
Access to heart failure care post emergency department visit: do we meet established benchmarks and does it matter?
Feldman DE, Huynh T, Lauriers JD, Giannetti N, Frenette M, Grondin F, Michel C, Sheppard R, Montigny M, Lepage S, Nguyen V, Behlouli H, Pilote L.Am Heart J. 2013 May;165(5):725-32. doi: 10.1016/j.ahj.2013.02.017. Epub 2013 Mar 21. PMID: 23622909
Effects of dalcetrapib in patients with a recent acute coronary syndrome.
Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS; dal-OUTCOMES Investigators (Lepage S).
N Engl J Med. 2012 Nov 29;367(22):2089-99. doi: 10.1056/NEJMoa1206797. Epub 2012 Nov 5. PMID: 23126252
RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome.
Steg PG, Mehta SR, Jukema JW, Lip GY, Gibson CM, Kovar F, Kala P, Garcia-Hernandez A, Renfurm RW, Granger CB;RUBY-1 Investigators (Lepage S).
Eur Heart J. 2011 Oct;32(20):2541-54. Epub 2011 Aug 30. PMID: 21878434
Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure.
Massie BM, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Weatherley BD, Cleland JG, Givertz MM, Voors A, DeLucca P, Mansoor GA, Salerno CM, Bloomfield DM, Dittrich HC; PROTECT Investigators and Committees (Lepage S).
N Engl J Med. 2010 Oct 7;363(15):1419-28. PMID: 20925544
Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function.
Weatherley BD, Cotter G, Dittrich HC, DeLucca P, Mansoor GA, Bloomfield DM, Ponikowski P, O'Connor CM, Metra M, Massie BM; PROTECT Steering Committee, Investigators, and Coordinators (Lepage S).
J Card Fail. 2010 Jan;16(1):25-35. Epub 2009 Dec 11. PMID: 20123315